

UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alcsandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	· FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/767,712	01/29/2004	Steven J. Coats	ORT 1375 CIP	5675	
27777	7590 08/22/2005		EXAMINER		
PHILIP S. JOHNSON JOHNSON & JOHNSON			KIFLE, BRUCK		
	SON & JOHNSON PLAZA	·	ART UNIT	PAPER NUMBER	
NEW BRUN	WICK, NJ 08933-7003		1624		
			DATE MAILED: 08/22/2005		

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)				
Office Action Summary		10/767,712	COATS ET AL.				
		Examiner	Art Unit				
		Bruck Kifle, Ph.D.	1624				
Period fo	The MAILING DATE of this communication a or Reply	appears on the cover sheet w	th the correspondence address	***			
THE - Exte after - If the - If NC - Failt Any	MAILING DATE OF THIS COMMUNICATION meions of time may be available under the provisions of 37 CFR SIX (6) MONTHS from the mailing date of this communication period for reply specified above is less than thirty (30) days, a roperiod for reply is specified above, the maximum statutory period for reply within the set or extended period for reply will, by state reply received by the Office later than three months after the may end patent term adjustment. See 37 CFR 1.704(b).	N. 1.136(a). In no event, however, may a reply within the statutory minimum of third od will apply and will expire SIX (6) MON tute, cause the application to become AE	reply be timely filed ty (30) days will be considered timely. ITHS from the mailing date of this communic 3ANDONED (35 U.S.C. & 133).	cation.			
Status							
1)⊠	Responsive to communication(s) filed on 29	January 2004.					
2a) <u></u> ☐	This action is FINAL . 2b)⊠ Th	nis action is non-final.					
3)[Since this application is in condition for allow closed in accordance with the practice under		-	ts is			
Disposit	ion of Claims	,	,				
4)⊠	Claim(s) 1-34 is/are pending in the application	าท					
	4a) Of the above claim(s) is/are withdrawn from consideration.						
	Claim(s) is/are allowed.						
	Claim(s) 1-34 is/are rejected.						
7)	Claim(s) is/are objected to.						
8)□	Claim(s) are subject to restriction and	l/or election requirement.					
Applicat	ion Papers						
9)[The specification is objected to by the Exami	ner.					
10)	The drawing(s) filed on is/are: a) a	ccepted or b) dojected to	by the Examiner.				
	Applicant may not request that any objection to the	ne drawing(s) be held in abeyan	ice. See 37 CFR 1.85(a).				
	Replacement drawing sheet(s) including the corre	_	· ·	` '			
11)[The oath or declaration is objected to by the	Examiner. Note the attached	Office Action or form PTO-152	2.			
Priority (ınder 35 U.S.C. § 119	•					
	Acknowledgment is made of a claim for foreion All b) Some * c) None of:	gn priority under 35 U.S.C. §	119(a)-(d) or (f).				
a)		nto boyo been received					
			anliantian Na				
	2. Certified copies of the priority docume3. Copies of the certified copies of the priority						
	application from the International Bure		received in this National Stage	;			
* 5	See the attached detailed Office action for a li	` ''	received.				
		33,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,					
Attachmen	t(s)						
	e of References Cited (PTO-892)		iummary (PTO-413)				
	e of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s	s)/Mail Date nformal Patent Application (PTO-152)				
	nation Disclosure Statement(s) (PTO-1449 or PTO/SB/0 r No(s)/Mail Date <u>1/29/04</u> .	6) Other:					

MC

Application/Control Number: 10/767,712

Art Unit: 1624

Claim Rejections - 35 USC § 112

Claims 1-34 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

- i) The last phrase of claims 1-3 reads "and pharmaceutically acceptable enantiomers, diastereomers and salts thereof." This is improper. Applicants may rewrite this phrase as "or enantiomers, diastereomers or pharmaceutically acceptable salts thereof." The claim should be rewritten using alternative language to be of proper Markush form.
- ii) The term "cycloalkyl" is indefinite because it is not known how many atoms make up the ring and what kind of a ring is intended (monocyclic, bicyclic, spiro, fused, bridged, saturated, etc.).
- iii) The term "heteroaryl" is indefinite because it is not known how many atoms are present, how many and what kind of heteroatoms are involved, what size ring is intended and how many rings are present.
- iv) The term "heterocyclyl" is indefinite because it is not known how many atoms make up the ring, which atoms are present and what kind of a ring (monocyclic, bicyclic, spiro, fused, bridged, saturated, etc.) is intended.

Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground

Page 2

Art Unit: 1624

provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 1-34 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-22 of U.S. Patent No. 6,552,036. Although the conflicting claims are not identical, they are not patentably distinct from each other because the claimed compounds and patented compounds overlap substantially. The instant claims differ from the patented claims by reciting specific species and a more limited genus. It would have been obvious to one having ordinary skill in the art at the time of the invention to select any of the species of the genus taught by the patent, including those instantly claimed, because the skilled artisan would have the reasonable expectation that any of the species of the genus would have similar properties and, thus, the same use as taught for the genus as a whole. One of ordinary skill in the art would have been motivated to select the claimed compounds from the genus in the patent since such compounds would have been suggested by the patent as a whole.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Bruck Kifle, Ph.D. whose telephone number is 571-272-0668. The examiner can normally be reached Tuesdays to Fridays between 8:30 AM and 6:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mr. James Wilson can be reached on 571-272-0661. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1624

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Bruck Kifle, Ph.D. Primary Examiner

Art Unit 1624

BK

August 17, 2005